C R Bard (BCR) Earns Coverage Optimism Score of 0.05

Headlines about C R Bard (NYSE:BCR) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. C R Bard earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 45.2035226576509 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

The stock has a market cap of $24,140.00, a price-to-earnings ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C R Bard has a 52-week low of $223.02 and a 52-week high of $337.73.

Several research firms have recently issued reports on BCR. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 target price for the company in a research note on Tuesday, December 26th. ValuEngine lowered shares of C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $320.83.

In other C R Bard news, VP John A. Deford sold 14,107 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $333.48, for a total transaction of $4,704,402.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jim C. Beasley sold 3,395 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $332.00, for a total transaction of $1,127,140.00. Following the sale, the insider now directly owns 25,630 shares in the company, valued at $8,509,160. The disclosure for this sale can be found here. 0.80% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This report was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.themarketsdaily.com/2018/03/14/c-r-bard-bcr-earns-coverage-optimism-score-of-0-05.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply